ABIOMED Inc

ABIOMED — Q2 2022 Earnings Presentation

7 slides from ABIOMED's earnings presentation, Oct 28, 2021

  1. Slide 1: Q2 FY 2022 Earnings Call: Financial Results & Operational Highlights

    ® Recovering Hearts. Saving Lives. Q2 FY 2022 Earnings Call Financial Results & Operational Highlights Recovering Hearts. Saving Lives.

  2. Slide 2: Financial Results, Q2 FY 2022

    2 FINANCIAL RESULTS, Q2 FY 2022 Fiscal Year ends March 31 Revenue ($M) & Growth Rates Cash* ($M) $253 $248 $241 $848 $862 $232 $788 $805 $210 $736 YOY +2% +5% +17% +53% +18% Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 Q2'21 Q3'21 Q4'21 Q1'22 Q2'22 *No debt Gross Margin % Operating Margin % 81.5% 82.3% 82.1% 82.3%

  3. Slide 3: U.S. Utilization Mix, Q2 FY 2022

    3 U.S. UTILIZATION MIX, Q2 FY 2022 Revenue by Impella® Device Utilization by Indication Impella 5.0® / 5.5 (18%) Other Impella RP® (4%) (4%) Emergent (55%) Impella 2.5® (3%) ® Impella CP ® Protected PCI (75%) (41%) U.S. Hospital Site Penetration Patient Performance Revenue Performance Impella® Devic

  4. Slide 4: ABIOMED FY 2022 Revenue Guidance

    4 ABIOMED FY 2022 REVENUE GUIDANCE Abiomed FY’22 Abiomed FY’22 Abiomed FY’22 Original Guidance Post-Q1 Guidance Post-Q2 Guidance Revenue Revenue Revenue $990M - $1.03B $1.03M - $1.05B $1.01B - $1.03B +17 - 22% YOY +22 - 24% YOY +19 - 22% YOY Operating Margin % Non-GAAP Operating Non-GAAP Operating 2

  5. Slide 5: Appendix

    5 APPENDIX FOR INVESTORS ONLY Recovering Hearts. Saving Lives.

  6. Slide 6: ABIOMED 2.0 Platform: Impella, ECMO, preCARDIA

    6 ABIOMED 2.0 PLATFORM: IMPELLA, ECMO, PRECARDIA PERCUTANEOUS INSERTION PRECARDIA Impella 2.5® Impella CP® with SmartAssist® 24/7 Support Onsite, On-call, Online Impella ECPTM FDA EFS* FDA EFS* RIGHT HEART ECMO Impella RP® >500 Global Field Reps Clinical Support Impella Connect® Center SURGICAL INSE

  7. Slide 7: Impella ECP “Expandable CP*”

    7 Impella ECP™ “Expandable CP*” Aortic Valve Aorta Ventricle Canula open only when pump Soft atraumatic is flowing polyurethane cannula • 9Fr catheter & pump at insertion across aortic valve • Pump expands to 18Fr • Designed for flows >3.5 L/min • Protected PCI® application (6-12 hr duration) • Gran

ABIOMED — Q2 2022 Earnings Presentation on 6ix